This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
He was appointed a Board member and the Chairman in 2012.
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)